{
    "nct_id": "NCT03076164",
    "official_title": "A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib",
    "inclusion_criteria": "* Pathologic evidence of advanced stage IV or recurrent lung adenocarcinoma reviewed at MSKCC\n* Somatic activating mutation in EGFR Radiographic progression during treatment with erlotinib.\n* Any number of prior chemotherapy regimens is permitted.\n* Measurable (RECIST 1.1) indicator lesion not previously irradiated\n* KPS >/= 70%\n* Age >18 years old\n* Must have undergone biopsy after development of acquired resistance to erlotinib with available archived tissue (equivalent of > 10 unstained slides)\n* Left ventricular Ejection Fraction >/= the lower limit of normal by ECHO or MUGA\n* Adequate organ function:\n* AST, ALT </= 2.5 x ULN\n* Total bilirubin </= 1.5 x ULN\n* Albumin>/=2.6g/dL - Creatinine < 1.5 x ULN OR calculated creatinine clearance >/=50mL/min\n* Absolute neutrophil count (ANC) >/= 1,200 cells/mm3\n* Hemoglobin>/=9.0 g/dL\n* Platelets >/=100,000/mm3\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with symptomatic brain metastasis requiring escalating doses of steroids\n* Patients with grade 2 or greater diarrhea prior to study initiation despite maximal medical management due to medications or a medical condition such as Crohn's disease or malabsorption\n* Pregnant or lactating women\n* Any type of systemic therapy (chemotherapy or experimental drugs) within 2 weeks of starting treatment on protocol except for a EGFR TKI\n* Patients who have received prior treatment with a MEK inhibitor\n* Any major surgery or extensive radiotherapy within 21 days of starting treatment on protocol.\n* A history of clinically significant interstitial lung disease or pneumonitis\n* Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study administration, New York Heart Association Class III or IV congestive heart failure, or symptomatic uncontrolled Arrythmias, prolonged corrected QT interval >480msec, treatment refractory hypertension, presence of a cardiac defibrillator\n* History of central serous retinopathy or retinal vein occlusion",
    "miscellaneous_criteria": ""
}